31 March 2020 → 30 June 2020
D

Description

The DIM ELICIT would like to support projects developing innovative technologies and methods regarding the analysis, diagnosis and/or treatment to fight SARS-CoV-2.

The technologies targeted in this call will have to belong to at least one Core technologies and one End-user applications:

  • Core technologies
    • Microfludics
    • Biophotonic and waves
    • Image analysis and Big Data
  • End-user applications
    • Single Cell/Single molecule
    • Organ on chips
    • Technologies for in vivo biology
    • High Tech – Low Cost technologies
    C

    Conditions

    Any research team from the Ile de France region can apply with a project linked to the infectious agent SARS-CoV-2, and in accordance with the DIM ELICIT’s goals, positioning and thematic axes.

    Applications will be assessed according to the following evaluation criteria:

    • Innovation and originality of the proposal
    • Scientific quality
    • Adequacy of resources with the proposed project

    The projects submitted must target the acquisition of knowledge with a potential impact expected within 18 months following the funding.

    Projects will have to be written in English.

    Applications must be sent to : dim.elicit@pasteur.fr

    We will acknowledge the receipt of the applications within two days and try to give you a feedback on your eligibility within a week after an evaluation of the direction committee of the program.

    This call will be open until the end of the crisis. The closure of the call will be notified on this page.

    R

    Rewards

    In the context of this call, the DIM ELICIT will fund for each project:

    • 15k€ for running and/or staff costs

    AND / OR

    • 30k€ for equipment (66% max of total cost without VAT)

     

     

    A

    Application Form

    Full description of the call can be downloaded by clicking here.

    I

    Additional Info

    Contact : For any question, please contact either dim.elicit@pasteur.fr or axel.bonetto@pasteur.fr.